VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

27 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

31 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

24 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

23 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

10 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

08 Aug 2023 07:30:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting

03 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

26 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

21 Jul 2023 16:24:31 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

10 May 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

09 May 2023 07:30:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma

12 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

06 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference

28 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

27 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

21 Feb 2023 07:22:36 By Nasdaq GlobeNewswire